The IBD SmartSelect Composite Rating for Catalyst Pharmaceuticals rose from 94 to 98 Friday.
The new score means the company is now outperforming 98% of all stocks in terms of the most important fundamental and technical stock-picking criteria. The top-performing stocks tend to have a 95 or better grade as they launch a significant move so be sure to keep that in mind when looking for the best stocks to buy and watch.
Catalyst Pharmaceuticals is currently forming a consolidation, with a 24.27 entry. See if the stock can break out in volume at least 40% above average.
Looking For Winning Stocks? How To Invest In Both Bull And Bear Markets
The stock earns a 95 EPS Rating, meaning its recent quarterly and longer-term annual earnings growth tops 95% of all stocks.
Its Accumulation/Distribution Rating of B- shows moderate buying by institutional investors over the last 13 weeks.
The company reported 0% earnings-per-share growth for Q3. Revenue growth climbed 25%, up from 23% in the prior quarter. The company has now posted rising growth in each of the last two quarters.
Catalyst Pharmaceuticals holds the No. 1 rank among its peers in the Medical-Biomed/Biotech industry group. Halozyme Therapeutics and ADMA Biologics are also among the group's highest-rated stocks.
